openPR Logo
Press release

PARP Inhibitors Market 10-Year Forecast and Trends Analysis Research Report

12-18-2017 02:00 PM CET | Health & Medicine

Press release from: Future Market Insights

/ PR Agency: Future Market Insights
PARP Inhibitors Market 10-Year Forecast and Trends Analysis

Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These PARP inhibitors used to treat subset of ovarian cancer. Currently only PARP inhibitors approved in the market is Lynparza from AstraZeneca and several PARP inhibitors are in late stage pipeline which are showing promising results in the recent released clinical trials data. The first PARP inhibitor from AstraZeneca approved in late 2014 and market witnessed significant gain in 2015. PARP inhibitors mainly indicated in few set of patients based molecular diagnostics. Several positive end points for these drugs are prolonged Progression Free Survival (PFS) and over survival rates.

PARP inhibitors Market: Drivers and Restraints

PARP inhibitors market is driven by promising pipeline products which are showing positive results in recent times and increasing awareness among healthcare professionals and patients. Apart from aforementioned drivers, PARP inhibitors market is driven by improved safety profile of these drugs compared to cell-therapy drugs and increased US FDA approval for these drugs and rising incidences of cancer over the forecast period.

Request Report TOC @ https://www.futuremarketinsights.com/toc/rep-gb-3197

PARP inhibitors market hindered by the small patient pool for the treatment, side effects associated with the drugs, drug resistance among patients and stringent regulatory requirement for the approvals of the PARP inhibitors over the forecast period. In addition, development of PARP inhibitors have been full of up and down and late stage recall of few developmental drugs expected to hinder the market revenue growth of PARP inhibitors over the forecast period.

PARP inhibitors Market: Overview

PARP inhibitors market is witnessing significant changes due to increasing opportunity owing to rush of big Pharma companies to buy the drug discovery companies like Tesaro and Clovis who’s pipeline PARP inhibitors shown positive results. Companies like Pfizer continuously looking for investing in the companies having product pipeline of PARP inhibitors. PARP inhibitors market is highly competitive as several small and large Pharma companies are having presence in the segment with promising pipeline products or marketed products.

Request to Sample Report - https://www.futuremarketinsights.com/reports/sample/rep-gb-3197

PARP inhibitors Market: Region-wise Outlook

Geographically, PARP inhibitors market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America and Europe will remain key market for PARP inhibitors market due to rising R&D activities by key players, better reimbursement policies, and availability of advanced healthcare infrastructure helps to maintain larger market share in the globalPARP inhibitors market by the regions over the forecast period. Asia Pacific PARP inhibitors market is anticipated to present lower growth opportunity owing to lack of regulatory protection for innovative drugs and reimbursement policies in the region.

PARP inhibitors Market: Key Players

Some of the players in the global PARP inhibitors market are AstraZeneca, AbbVie, Clovis Oncology, Medivation and Tesaro to name a few.

Pre Book Full Report – https://www.futuremarketinsights.com/checkout/3197

ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

CONTACT:
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website :www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release PARP Inhibitors Market 10-Year Forecast and Trends Analysis Research Report here

News-ID: 865775 • Views:

More Releases from Future Market Insights

Germany Flexible Protective Packaging Market Poised for Significant Growth at 6.4% Through 2035 Driven by Innovation, Sustainability, and Expanding E-Commerce Demand
Germany Flexible Protective Packaging Market Poised for Significant Growth at 6. …
The global flexible protective packaging market is set for remarkable growth over the next decade, with its value estimated at USD 14.6 billion in 2025 and projected to reach USD 25.1 billion by 2035, registering a compound annual growth rate (CAGR) of 5.6%. This expansion reflects the rising adoption of lightweight, durable, and cost-efficient packaging solutions across industries ranging from electronics and consumer goods to pharmaceuticals and e-commerce. The market has
Low Density Polyethylene Packaging Market Set to Expand Steadily from USD 21.8 Billion in 2025 to USD 34.5 Billion by 2035
Low Density Polyethylene Packaging Market Set to Expand Steadily from USD 21.8 B …
The global low density polyethylene (LDPE) packaging market is experiencing a steady growth trajectory, with its value estimated at USD 21.8 billion in 2025 and projected to reach USD 34.5 billion by 2035. This expansion, reflecting a compound annual growth rate (CAGR) of 4.7%, is driven by the versatility, cost-effectiveness, and durability of LDPE materials across diverse packaging applications. From flexible films to robust containers, LDPE continues to provide manufacturers
Recycled Ocean Plastic Packaging Market Poised for Rapid Growth as Sustainability Drives Global Adoption
Recycled Ocean Plastic Packaging Market Poised for Rapid Growth as Sustainabilit …
The recycled ocean plastic packaging market is charting a remarkable growth trajectory, estimated at USD 723.1 million in 2025 and projected to soar to USD 2,206.1 million by 2035, reflecting a robust compound annual growth rate (CAGR) of 11.8%. This surge is propelled by growing environmental awareness, regulatory initiatives targeting marine pollution, and rising consumer preference for eco-friendly packaging solutions across food, beverage, personal care, and consumer goods sectors. Early Adoption
Germany Blown Stretch Packaging Films Market Poised for Steady Growth at 4.3% by 2035 Through Innovation
Germany Blown Stretch Packaging Films Market Poised for Steady Growth at 4.3% by …
The global blown stretch packaging films market is on a clear growth trajectory, with its value projected to rise from USD 3.2 billion in 2025 to USD 4.6 billion by 2035, reflecting a compound annual growth rate (CAGR) of 3.7%. This market expansion is underpinned by increasing demand across logistics, e-commerce, food and beverage, and industrial sectors. Manufacturers are actively adopting innovative solutions to enhance packaging efficiency, sustainability, and cost-effectiveness,

All 5 Releases


More Releases for PARP

PARP Inhibitor Biomarkers Market Size to Expand Lucratively by 2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global PARP Inhibitor Biomarkers Market - (By Product (Kits, Assays), By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, Others), By Application (Breast Cancer, Ovarian Cancer, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global PARP Inhibitor Biomarkers Market is valued at US$ 879.8
Parp Inhibitors Market Driven by Demand for Immersive Technologies Across Indust …
Global Parp Inhibitors Market Impact of AI and Automation The PARP inhibitors market has seen remarkable growth in recent years, primarily driven by advances in cancer treatment and the increasing prevalence of cancer globally. These inhibitors, which block the enzyme poly (ADP-ribose) polymerase (PARP), are proving to be highly effective in targeting specific cancer cells, especially in cancers with DNA repair deficiencies like ovarian, breast, and prostate cancers. The approval of
China Market Analysis of PARP Inhibitors: Growth Opportunities
Global PARP Inhibitors Market: Introduction A PARP (poly ADP-ribose polymerase) inhibitor is a substance that blocks PARP enzyme in the cell. DNA damage occurs during cancer. Blocking of PARP helps the cancer cells in repairing their damaged part of DNA. Read Report Overview - https://www.transparencymarketresearch.com/parp-inhibitors-market.html Global PARP Inhibitors Market: Competition Landscape Key players operating in the global PARP inhibitors market are AstraZeneca, Tesaro, AbbVie Inc., Medivation, and Clovis Oncology. The global market is
PARP Inhibitors Market Trends and Segments
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These
PARP Inhibitors Market Dynamics, Segments, Size and Demand, 2017 - 2027
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These
Global PARP Inhibitor Market: Size, Trends And Forecasts (2016-2020)
Scope of the Report The report titled Global PARP Inhibitor Market: Size, Trends and Forecasts (2016-2020) provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib. The report analyses the global Lynparza market in detail along with the regional analysis as